Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.
Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-van den Brekel JA, Smit EF, Krouwels FH, Wilschut FA, Hiltermann TJN, Timens W, Schuuring E, Janssen JDJ, Goosens M, van den Berg PM, de Langen AJ, Stigt JA, van den Borne BEEM, Groen HJM, van Geffen WH, van der Wekken AJ. Gijtenbeek RGP, et al. Among authors: de langen aj. ERJ Open Res. 2022 Oct 17;8(4):00239-2022. doi: 10.1183/23120541.00239-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36267895 Free PMC article.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. Among authors: de langen aj. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Free PMC article. Clinical Trial.
Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges.
van Aken ESM, van der Linden YM, van Thienen JV, de Langen AJ, Marijnen CAM, de Jong MC; Dutch Platform for Palliative Radiotherapy (LPPR). van Aken ESM, et al. Among authors: de langen aj, de jong mc. Clin Transl Radiat Oncol. 2022 Jan 28;33:93-98. doi: 10.1016/j.ctro.2022.01.002. eCollection 2022 Mar. Clin Transl Radiat Oncol. 2022. PMID: 35243019 Free PMC article.
"Finding my way in a maze while the clock is ticking": The daily life challenges of adolescents and young adults with an uncertain or poor cancer prognosis.
Burgers VWG, van den Bent MJ, Dirven L, Lalisang RI, Tromp JM, Compter A, Kouwenhoven M, Bos MEMM, de Langen A, Reuvers MJP, Franssen SA, Frissen SAMM, Harthoorn NCGL, Dickhout A, Noordhoek MJ, van der Graaf WTA, Husson O. Burgers VWG, et al. Front Oncol. 2022 Nov 15;12:994934. doi: 10.3389/fonc.2022.994934. eCollection 2022. Front Oncol. 2022. PMID: 36457502 Free PMC article.
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
van der Wel JWT, Jebbink M, van den Broek D, Steinbusch LC, Theelen WSME, Ruiter G, Buikhuisen W, Burgers JA, Baas P, Vermeulen M, van der Noort V, Hashemi SMS, Bosch LJW, Monkhorst K, Smit EF, Boelens MC, de Langen AJ. van der Wel JWT, et al. Among authors: de langen aj. Lung Cancer. 2024 Dec;198:107972. doi: 10.1016/j.lungcan.2024.107972. Epub 2024 Sep 28. Lung Cancer. 2024. PMID: 39556978
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ. Verkerk K, et al. Among authors: de langen aj. Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925. Clin Cancer Res. 2024. PMID: 39352721 Clinical Trial.
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies.
Qi Z, Ha T, Feng W, Karnoub M, Pereira K, Shiga R, Smit EF, Goto Y, De Langen AJ, Goto K, Velasco Roth AM, Khambata-Ford S. Qi Z, et al. Among authors: de langen aj. Arch Pathol Lab Med. 2024 Sep 20. doi: 10.5858/arpa.2024-0014-OA. Online ahead of print. Arch Pathol Lab Med. 2024. PMID: 39299708 Free article.
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study.
van der Wel JWT, Boelens MC, Jebbink M, Smulders SA, Maas KW, Luitse MJA, Compter A, Boltjes RPB, Sol N, Monkhorst K, van den Broek D, Smit EF, de Langen AJ, Brandsma D. van der Wel JWT, et al. Among authors: de langen aj. Neuro Oncol. 2024 Dec 5;26(12):2316-2327. doi: 10.1093/neuonc/noae138. Neuro Oncol. 2024. PMID: 39110039
101 results